Selonsertib
Based on 25 publication(s) in Google Scholar
Selonsertib (GS-4997), an orally bioavailable, selective apoptosis signal-regulating kinase 1 (ASK1) inhibitor with a pIC50 of 8.3, has been evaluated as an experimental treatment for diabetic nephropathy and kidney fibrosis.
For research use only. We do not sell to patients.
- Purity: 99.05%
- CAS No.: 1448428-04-3
- Formula: C24H24FN7O
- Molecular Weight:445.49
-
Storage:Powder -20°C, 3 years , 4°C, 2 years ; In solvent -80°C, 1 year , -20°C, 6 months
To place orders, for customer services and technical support, please contact: MedChemExpress USA
Tel: 609-228-6898 E-mail: [email protected] [email protected]
-
Biological Activity
-
Chemical Information
-
Solvent & Solubility
- Purity & Documentation
- References
-
Help & FAQs
-
Apoptosis Compound Library
HY-L003
-
Immunology/Inflammation Compound Library
HY-L007
-
Kinase Inhibitor Library
HY-L009
-
MAPK Compound Library
HY-L010
-
Anti-Cancer Compound Library
HY-L025
-
Clinical Compound Library
HY-L026
-
Drug Repurposing Compound Library
HY-L035
-
Anti-diabetic Compound Library
HY-L040
-
Oxygen Sensing Compound Library
HY-L045
-
Orally Active Compound Library
HY-L061
-
Anti-Obesity Compound Library
HY-L087
-
Targeted Diversity Library
HY-L099
-
Rare Diseases Drug Library
HY-L102
-
Heterocyclic Compound Library
HY-L138
-
Highly Selective Inhibitors Library
HY-L158
-
Highly Selective Activators Library
HY-L159
-
Cell Death Library
HY-L162
-
Serine/Threonine Kinase Inhibitor Library
HY-L164
-
Bioactive Compound Library Max
HY-L181
-
Kinase Inhibitor Library Mini
HY-L009M
-
MCE Bioactive Compound Library
HY-L001V
-
Drug Repurposing Compound Library Plus
HY-L035P
-
Clinical Compound Library Plus
HY-L026P
-
Bioactive Compound Library
HY-L001
-
Anti-Fibrosis Compound Library
HY-L185
-
Non-Alcoholic Fatty Liver Disease (NAFLD) Compound Library
HY-L199
-
High-Throughput Bioactive Compound Library
HY-L205
-
Posttranslational Modification Library
HY-L226
Publications Citing Use of MedChemExpress (MCE) Selonsertib
More- Acta Pharm Sin B. 2025 Sep;15(9):4789-4806. [Abstract]
- Biomaterials. 2022 Nov:290:121817. [Abstract]
- J Hazard Mater. 2021 Jun 5:411:125179. [Abstract]
- Cell Death Dis. 2023 Aug 26;14(8):561. [Abstract]
- Acta Pharmacol Sin. 2025 Jun 11. [Abstract]
- Phytomedicine. 2023 Mar:111:154646. [Abstract]
- Apoptosis. 2026 Apr 17;31(4):127. [Abstract]
- Basic Res Cardiol. 2026 Jun;121(3):459-479. [Abstract]
- Phytother Res. 2023 Apr;37(4):1274-1292. [Abstract]
- Cell Biosci. 2021 Jan 7;11(1):9. [Abstract]
- Life Sci. 2026 Mar 1:388:124173. [Abstract]
- Commun Biol. 2025 May 21;8(1):781. [Abstract]
- Int Immunopharmacol. 2026 Mar 1:172:116121. [Abstract]
- Int Immunopharmacol. 2023 Jan:114:109563. [Abstract]
- Cancers (Basel). 2022 Dec 15;14(24):6206. [Abstract]
- FASEB J. 2025 Dec 15;39(23):e71311. [Abstract]
- Biochim Biophys Acta Mol Basis Dis. 2022 Dec 1;1868(12):166553. [Abstract]
- Sci Rep. 2024 Mar 11;14(1):5885. [Abstract]
- Neurochem Res. 2022 Dec;47(12):3829-3837. [Abstract]
- Animal Model Exp Med. 2025 Jan;8(1):102-113. [Abstract]
- PLoS One. 2024 Nov 1;19(11):e0308647. [Abstract]
- bioRxiv. 2026 Jan 25.
- University of Oxford. 2023 Oct.
- Research Square Print. 2022 Aug.
- Research Square Preprint. 2021 Jul.
Customer Validation & Images
-
IF
-
Others
-
Histological Imaging/Staining
-
ELISA
-
IHC
All MAP3K Isoforms
More
Biological Activity
|
ASK1 8.3 (pIC50) |
|
Cell Line
|
Type | Value | Description | References |
|---|---|---|---|---|
| HEK-293T | IC50 |
20 nM
Compound: 4; GS-4997
|
Inhibition of V5 tagged human ASK1 expressed in HEK-293T cells assessed as reduction in T838 autophosphorylation incubated for 1 hr
Inhibition of V5 tagged human ASK1 expressed in HEK-293T cells assessed as reduction in T838 autophosphorylation incubated for 1 hr
|
[PMID: 31710475] |
| HEK-293T | IC50 |
20 nM
Compound: 3
|
Inhibition of V5 tagged human ASK1 expressed in HEK293T cells assessed as reduction in T848 autophosphorylation incubated for 1 hr by MSD assay
Inhibition of V5 tagged human ASK1 expressed in HEK293T cells assessed as reduction in T848 autophosphorylation incubated for 1 hr by MSD assay
|
[PMID: 32292554] |
| HepG2 | IC50 |
20 μM
Compound: 1; GS-4997
|
Cytotoxicity against human HepG2 cells assessed as inhibition of cell growth
Cytotoxicity against human HepG2 cells assessed as inhibition of cell growth
|
[PMID: 32289582] |
Selonsertib (GS-4997) is a clinical stage ASK1 inhibitor, which has been evaluated as an experimental treatment for diabetic nephropathy and kidney fibrosis[1]. Selonsertib (GS-4997) is a highly selective and potent once-daily oral ASK1 inhibitor that competes with ATP in the ASK1 catalytic kinase domain[2].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
| NCT Number | Sponsor | Condition | Start Date |
Phase
|
|---|---|---|---|---|
| NCT01329991 | Plexxikon| | 2011-05 | PHASE1 |
Chemical Information
-
CAS No. 1448428-04-3
-
Appearance Solid
-
Molecular Weight 445.49
-
Formula C24H24FN7O
-
Color White to light yellow
-
SMILES
O=C(NC1=NC(C2=NN=CN2C(C)C)=CC=C1)C3=CC(N4C=C(C5CC5)N=C4)=C(C)C=C3F
-
Synonyms
GS-4997
-
Shipping
Room temperature in continental US; may vary elsewhere.
-
Storage
Powder -20°C 3 years 4°C 2 years In solvent -80°C 1 year -20°C 6 months
Publications (25)
-
Journal Impact Factor
-
Most Recent
-
Acta Pharm Sin B
Palmitoylated SARM1 targeting P4HA1 promotes collagen deposition and myocardial fibrosis: A new target for anti-myocardial fibrosis. [Abstract]2025 Sep;15(9):4789-4806. PMID: 41049740
Selonsertib purchased from MedChemExpress. Usage Cited in: Acta Pharm Sin B. 2025 Sep;15(9):4789-4806. [Abstract]
Immunofluorescence in determining the expression of P4HA1 after treated with Berberine (BBC; p.o.; 20 mg/kg for 7 days ) and Selonsertib (p.o.; 20 mg/kg for 7 days ) in the heart tissue of MI mice. n=3. *P < 0.05, **P < 0.01 vs. Sham, #P < 0.05, ##P < 0.01 vs. MI. Scale bar, 200 µm.
Selonsertib purchased from MedChemExpress. Usage Cited in: Acta Pharm Sin B. 2025 Sep;15(9):4789-4806. [Abstract]
Echocardiographic detection of cardiac function changes in MI mice and treated with Berberine (BBC; p.o.; 20 mg/kg for 7 days ) and Selonsertib (p.o.; 20 mg/kg for 7 days ) . n=3-4. *P < 0.05 vs. Sham, #P < 0.05 vs. MI.
-
Biomaterials
2022 Nov:290:121817. PMID: 36208587
Selonsertib purchased from MedChemExpress. Usage Cited in: Biomaterials. 2022 Nov:290:121817. [Abstract]
Selonsertib (Selon; 10 μM; 10 days) slightly decreased the lipid uptake in the MCLS culture.
Selonsertib purchased from MedChemExpress. Usage Cited in: Biomaterials. 2022 Nov:290:121817. [Abstract]
Selonsertib (Selon; 10 μM; 48 h) slightly decreased the expression of Collagen 1 and lipid accumulation in the MCLS culture.
-
J Hazard Mater
Combined exposure of alumina nanoparticles and chronic stress exacerbates hippocampal neuronal ferroptosis via activating IFN-γ/ASK1/JNK signaling pathway in rats. [Abstract]2021 Jun 5:411:125179. PMID: 33858114 -
Cell Death Dis
Targeted inhibition of protein synthesis renders cancer cells vulnerable to apoptosis by unfolded protein response. [Abstract]2023 Aug 26;14(8):561. PMID: 37626037 -
Acta Pharmacol Sin
Targeting PPARα activation sensitizes glioblastoma cells to temozolomide and reverses acquired resistance by inhibiting H3K18 lactylation. [Abstract]2025 Jun 11. PMID: 40500345 -
Phytomedicine
Apigenin ameliorates non-eosinophilic inflammation, dysregulated immune homeostasis and mitochondria-mediated airway epithelial cell apoptosis in chronic obese asthma via the ROS-ASK1-MAPK pathway. [Abstract]2023 Mar:111:154646. PMID: 36645975 -
Apoptosis
2026 Apr 17;31(4):127. PMID: 41995771 -
Basic Res Cardiol
Deubiquitinase USP43 exacerbates myocardial ischemia-reperfusion injury by stabilizing ASK1 and activating the JNK/P38 MAPK pathway. [Abstract]2026 Jun;121(3):459-479. PMID: 42012501 -
Phytother Res
Perilla frutescens L. alleviates trimethylamine N-oxide-induced apoptosis in the renal tubule by regulating ASK1-JNK phosphorylation. [Abstract]2023 Apr;37(4):1274-1292. PMID: 36420586
Selonsertib purchased from MedChemExpress. Usage Cited in: Phytother Res. 2023 Apr;37(4):1274-1292. [Abstract]
Selonsertib (5 µM) alleviates TMAO-induced morphological changes and improve cellular viability in RTEC cells.
-
Cell Biosci
Selonsertib, a potential drug for liver failure therapy by rescuing the mitochondrial dysfunction of macrophage via ASK1-JNK-DRP1 pathway. [Abstract]2021 Jan 7;11(1):9. PMID: 33413667 -
Life Sci
Galectin-9 in human trophoblast cells: Implications for maternal-fetal immune balance and pregnancy complications. [Abstract]2026 Mar 1:388:124173. PMID: 41544754 -
Commun Biol
2025 May 21;8(1):781. PMID: 40399666
Selonsertib purchased from MedChemExpress. Usage Cited in: Commun Biol. 2025 May 21;8(1):781. [Abstract]
Selonsertib (15 mg/kg; IP; daily) reduced exaggerated inflammation in NOD1-KO mice.
Selonsertib purchased from MedChemExpress. Usage Cited in: Commun Biol. 2025 May 21;8(1):781. [Abstract]
Selonsertib (15 mg/kg; IP; daily) reduced plasma IL-1β levels in the NOD1-KO mice.
Selonsertib purchased from MedChemExpress. Usage Cited in: Commun Biol. 2025 May 21;8(1):781. [Abstract]
Selonsertib (15 mg/kg; IP; daily) reduced IL-1β (magenta) and DAPI (blue) in the coronary arteries of NOD-KO mice.
-
Int Immunopharmacol
Monocrotaline induces liver injury via TRX1-ASK1-JNK Axis-mediated mitochondrial damage in hepatocytes. [Abstract]2026 Mar 1:172:116121. PMID: 41519004 -
Int Immunopharmacol
2023 Jan:114:109563. PMID: 36513021 -
Cancers (Basel)
Coxsackievirus Group B3 Has Oncolytic Activity against Colon Cancer through Gasdermin E-Mediated Pyroptosis. [Abstract]2022 Dec 15;14(24):6206. PMID: 36551691 -
FASEB J
E3 Ubiquitin Ligase TRIM21 Exacerbates Pathological Cardiac Hypertrophy Through ASK1 K63-Linked Polyubiquitination. [Abstract]2025 Dec 15;39(23):e71311. PMID: 41359290 -
Biochim Biophys Acta Mol Basis Dis
PUMA overexpression dissociates thioredoxin from ASK1 to activate the JNK/BCL-2/BCL-XL pathway augmenting apoptosis in ovarian cancer. [Abstract]2022 Dec 1;1868(12):166553. PMID: 36122664 -
Sci Rep
Digital pathology with artificial intelligence analysis provides insight to the efficacy of anti-fibrotic compounds in human 3D MASH model. [Abstract]2024 Mar 11;14(1):5885. PMID: 38467661 -
Neurochem Res
Anti-neuroinflammatory Effects and Brain Pharmacokinetic Properties of Selonsertib, an Apoptosis signal-regulating Kinase 1 Inhibitor, in mice. [Abstract]2022 Dec;47(12):3829-3837. PMID: 36309631 -
Animal Model Exp Med
Targeting ASK1 by CS17919 alleviates kidney- and liver-related diseases in murine models. [Abstract]2025 Jan;8(1):102-113. PMID: 38873818 -
PLoS One
A novel small molecule screening assay using normal human chondrocytes toward osteoarthritis drug discovery. [Abstract]2024 Nov 1;19(11):e0308647. PMID: 39485774 -
-
-
-
Solvent & Solubility
DMSO : 66.67 mg/mL (149.66 mM; ultrasonic and warming and heat to 60°C; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 1 year; -20°C, 6 months. When stored at -80°C, please use it within 1 year. When stored at -20°C, please use it within 6 months.
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 1 year; -20°C, 6 months. When stored at -80°C, please use it within 1 year. When stored at -20°C, please use it within 6 months.
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
Select the appropriate dissolution method based on your experimental animal and administration route.
- For the following dissolution methods, please ensure to first prepare a clear stock solution using an In Vitro approach and then sequentially add co-solvents:
- To ensure reliable experimental results, the clarified stock solution can be appropriately stored based on storage conditions. As for the working solution for In Vivo experiments, it is recommended to prepare freshly and use it on the same day.
- The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.
Add each solvent one by one: 10% DMSO 40% PEG300 5% Tween-80 45% Saline
Solubility: ≥ 2.08 mg/mL (4.67 mM); Clear solution
This protocol yields a clear solution of ≥ 2.08 mg/mL (saturation unknown).
Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (20.8 mg/mL) to 400 μL PEG300, and mix evenly; then add 50 μL Tween-80 and mix evenly; then add 450 μL Saline to adjust the volume to 1 mL.
Preparation of Saline: Dissolve 0.9 g sodium chloride in ddH₂O and dilute to 100 mL to obtain a clear Saline solution.
Add each solvent one by one: 10% DMSO 90% (20% SBE-β-CD in Saline)
Solubility: ≥ 2.08 mg/mL (4.67 mM); Clear solution
This protocol yields a clear solution of ≥ 2.08 mg/mL (saturation unknown).
Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (20.8 mg/mL) to 900 μL 20% SBE-β-CD in Saline, and mix evenly.
Preparation of 20% SBE-β-CD in Saline (4°C, storage for one week): 2 g SBE-β-CD powder is dissolved in 10 mL Saline, completely dissolve until clear.
Please enter the basic information of animal experiments:
-
-
-
-
Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.
Please enter your animal formula composition:
-
%DMSO +
Recommended: Keep the proportion of DMSO in working solution below 2% if your animal is weak.
-
%+
-
+%Tween-80 + +
-
%Saline +
The co-solvents required include: DMSO, . All of co-solvents are available by MedChemExpress (MCE). , Tween 80. All of co-solvents are available by MedChemExpress (MCE).
Working solution concentration: 0.22 mg/mL
Method for preparing stock solution: mg drug dissolved in μL DMSO. Stock solution concentration: mg/mL.
1. Take μL DMSO stock solution;
2. Add μL .
μL , mix evenly;
3. Then add μL Tween 80, mix evenly;
4. Then add μL
Please ensure that the stock solution in the first step is dissolved to a clear state, and add co-solvents in sequence. You can use ultrasonic heating (ultrasonic cleaner, recommended frequency 20-40 kHz), vortexing, etc. to assist dissolution.
Purity & Documentation
-
Data Sheet (273 KB)
-
SDS (419 KB)
- English - EN (419 KB)
- Français - FR (419 KB)
- Deutsch - DE (419 KB)
- Norwegian - NO (419 KB)
- Español - ES (419 KB)
- Swedish - SV (419 KB)
- Italian - IT (419 KB)
- Korean - KR (419 KB)
- Portuguese - PT (419 KB)
-
Handling Instructions (2659 KB)
References
[1]. Lanier M, et al. Structure-Based Design of ASK1 Inhibitors as Potential Agents for Heart Failure. ACS Med Chem Lett. 2017 Feb 8;8(3):316-320. [Content Brief]
[2]. Lin JH, et al. Design of a phase 2 clinical trial of an ASK1 inhibitor, GS-4997, in patients with diabetic kidney disease. Nephron. 2015;129(1):29-33. [Content Brief]
[3]. Loomba R, et al. The ASK1 inhibitor selonsertib in patients with nonalcoholic steatohepatitis: A randomized, phase 2trial. Hepatology. 2018 Feb;67(2):549-559. [Content Brief]
Complete Stock Solution Preparation Table
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 1 year; -20°C, 6 months. When stored at -80°C, please use it within 1 year. When stored at -20°C, please use it within 6 months.
| Optional Solvent | Concentration Solvent Mass | 1 mg | 5 mg | 10 mg | 25 mg |
|---|---|---|---|---|---|
| DMSO | 1 mM | 2.2447 mL | 11.2236 mL | 22.4472 mL | 56.1180 mL |
| 5 mM | 0.4489 mL | 2.2447 mL | 4.4894 mL | 11.2236 mL | |
| 10 mM | 0.2245 mL | 1.1224 mL | 2.2447 mL | 5.6118 mL | |
| 15 mM | 0.1496 mL | 0.7482 mL | 1.4965 mL | 3.7412 mL | |
| 20 mM | 0.1122 mL | 0.5612 mL | 1.1224 mL | 2.8059 mL | |
| 25 mM | 0.0898 mL | 0.4489 mL | 0.8979 mL | 2.2447 mL | |
| 30 mM | 0.0748 mL | 0.3741 mL | 0.7482 mL | 1.8706 mL | |
| 40 mM | 0.0561 mL | 0.2806 mL | 0.5612 mL | 1.4029 mL | |
| 50 mM | 0.0449 mL | 0.2245 mL | 0.4489 mL | 1.1224 mL | |
| 60 mM | 0.0374 mL | 0.1871 mL | 0.3741 mL | 0.9353 mL | |
| 80 mM | 0.0281 mL | 0.1403 mL | 0.2806 mL | 0.7015 mL | |
| 100 mM | 0.0224 mL | 0.1122 mL | 0.2245 mL | 0.5612 mL |
Selonsertib Related Classifications
HY-18938 Related Classifications
Powered by Bioz